Target Discovery for Drug Development Using Mendelian Randomization.

Area of Science:

• Pharmacology
• Genetics
• Epidemiology

Background:

• Drug development is costly and inefficient, with high failure rates.
• Human genetic approaches offer a powerful tool to identify causal drug targets and reduce translational barriers.
• Genetic information can elucidate causal relationships between drug targets and disease phenotypes.

Purpose of the Study:

• To review the theory and application of Mendelian randomization (MR) for prioritizing drug targets.
• To describe a protocol for performing two-sample MR (2SMR) using summary genome-wide association study (GWAS) data.
• To illustrate the utility of 2SMR with an example investigating the link between LDL and coronary artery disease (CAD).

Main Methods:

• Review of MR theory, including assumptions, analytical methods, and robustness to assumption violations.
• Detailed protocol for conducting 2SMR using summary GWAS data.
• Application of 2SMR to assess the causal relationship between low-density lipoprotein (LDL) and coronary artery disease (CAD).

Main Results:

• MR provides a framework for inferring causality from observational genetic data.
• The described 2SMR protocol facilitates efficient drug target prioritization.
• The LDL-CAD example demonstrates the practical application and potential of MR in drug discovery.

Conclusions:

• Mendelian randomization is a valuable tool for enhancing drug development efficiency by identifying robust causal drug targets.
• Utilizing human genetic data through MR can de-risk drug development and accelerate the discovery of effective therapeutics.
• The presented 2SMR methodology and example provide a practical guide for researchers aiming to leverage genetic insights for drug discovery.